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ABSTRACT 
Background and aims: Limited evidence has been available on the relationship between 
apoptosis with cardiovascular disease in population-based samples. We examined whether blood 
soluble Fas are associated with mortality from cardiovascular diseases. 
Methods: In a nested case-control study under a large prospective cohort; the Japan 
Collaborative Cohort (JACC) Study, where a total of 39,242 subjects 40 to 79 years of age 
provided serum samples and followed up for 9 years, we measured blood soluble Fas (sFas) 
levels among cases and controls, matched for sex, age, area of residence and year of serum 
storage. Conditional logistic regression models were used to calculate odds ratio (95%CI) of 
mortality from stroke and stroke subtypes according to quartiles and 1-SD increment of sFas 
levels.  
Results: During the follow-up (1988 to 1997), we identified 233 (121 in men and 112 in women) 
deaths from total stroke, comprising of 49 (18 and 31) subarachnoid hemorrhages, 55 (27 and 28) 
intraparenchymal hemorrhages, and 71 (44 and 27) ischemic strokes, and 97 (53 and 44) 
coronary heart diseases. After adjustment for cardiovascular risk factors, the multivariable odds 
ratio (95%CI) of subarachnoid hemorrhage associated with a 1-SD increment of sFas (1.3 ng/ml 
in both men and women) was 4.04 (1.07-15.3; P =0.04). No association was found between blood 
sFas levels and risks of intraparenchymal hemorrhage, ischemic stroke or coronary heart disease.  
Conclusions: Higher blood sFas levels were associated with higher mortality from subarachnoid 
hemorrhage, suggesting a potential role of apoptosis factors in the development or prognosis of 
subarachnoid hemorrhage. 
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Introduction 
One of the major challenges in cardiovascular medicine is to develop a tool for predicting the risk 
that an individual will suffer an acute cardiovascular event. During the last few decades, there has 
been a great interest in finding diagnostic and prognostic biomarkers that can be detected in blood 
long before an event may occur (1-3). In addition to established biomarkers such as lipid and 
glucose abnormalities, new biomarkers have been explored to enhance prediction for 
cardiovascular disease. The Fas (also called Apo-1 or CD95) system is an apoptosis-signaling 
receptor located on the cell surface that belongs to the tumor necrosis factor receptor family (4). 
Apoptosis may be linked to the pathogenesis of cardiovascular disease (CVD) (5) including 
subarachnoid hemorrhage (6,7); however no evidence has been available on the prospective 
associations between blood sFas and risk of CVD. Most of the previous studies were limited to 
describe an activation of the Fas system after the onset of coronary heart disease (CHD) (8-10), 
congestive heart failure (11,12) and cerebrovascular diseases (13,14). 
 We therefore investigated the associations between blood sFas levels and mortality from 
stroke and its subtypes including subarachnoid hemorrhage among middle-aged Japanese men 
and women by a nested-case control study under a nation-wide large prospective study.  
 
Methods 
Survey Population  
We conducted a nested case-control study as part of the Japan Collaborative Cohort Study 
(JACC) sponsored by the Ministry of Education and Science, which was first conducted in 1988-
1990 and involved 110,585 participants (46,395 men and 64,190 women, age 40-79 years) living 
in 45 communities throughout Japan who completed self-administered questionnaires about their 
lifestyles and medical histories of previous cardiovascular disease and cancer (15). Informed 
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consent was obtained from the participants when they completed the questionnaire. In several 
communities, informed consent was obtained at community level after the study purpose, 
methods and data confidentiality had been explained to community leaders and mayors.  
A total of 39,242 subjects (35.4% of the questionnaire respondents) provided blood 
samples after giving individual informed consent (16). After 557 men and 916 women with a 
history of cardiovascular disease or cancer at baseline had been excluded, a total of 37,769 
subjects (13,282 men and 24,487 women) were enrolled in the study presented here, which was 
approved by the Ethics Committees of the University of Tsukuba and Osaka University. 
 
Mortality Surveillance 
The participants were followed up to determine mortality of cardiovascular disease by the end of 
1997. For mortality surveillance in individual communities, investigators conducted systematic 
reviews of the death certificates, all of which were forwarded to the public health center in the 
area of residency. Mortality data were centralized at the Ministry of Health and Welfare, and the 
underlying cause of death was coded according to the International Classification of Diseases 
(ICD), 9th revision, for deaths from 1988 to 1994, and the 10th revision for deaths from 1995 to 
1997 as used for the National Vital Statistics. Registration of death is required by the Family 
Registration Law of Japan and is believed to be adhered to throughout Japan. All deaths 
occurring in the cohort were thus ascertained by death certificates from a public health center, 
except for subjects who died after moving away from their original community and were treated 
as censored cases.  
The ICD 9th and 10th revisions were used to determine cause-specific mortality of 
cardiovascular disease as follows: coronary heart disease (410 to 414, I20 to I25) and total stroke 
(ICD 9th revision, codes 430 to 438, ICD 10th revision, codes I60 to I69) including 
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intraparenchymal hemorrhage (431, I61), subarachnoid hemorrhage (430, I60), ischemic stroke 
(433 to 434, I63) and unclassified type of stroke. For each case, one control subject was selected 
randomly from participants without mortality from stroke or coronary heart disease, and matched 
for sex, age (±5years), community and year of blood drawing. 
 
Determination of biochemical variables 
Sera were prepared from blood samples as soon as possible after blood collection at laboratories 
in or near the surveyed municipalities. The serum from each participant was divided over 3-5 
tubes (300 μl per tube), and stored at –80°C until analysis in a single laboratory (SRL, Inc., 
Hachioji, Japan); none of the samples had been defrosted (17). Blood sFas levels were measured 
by enzyme-linked immuno-adsorbent assay (ELISA), using commercially available kits (MBL 
Co., Ltd., Nagoya). Since sFas levels were systematically low in one area (no. of stroke cases =2), 
we excluded all sera from that area from the analysis. All assays were performed and interpreted 
by individuals who were blinded to the case-control status of samples (18). The intra-assay 
precisions obtained using different reference sera for each determination method was 2.1% to 
5.5% of the coefficients variation values. The inter-assay coefficient of variance was 8.2% to 
12.3%. 
Serum total cholesterol was measured using the enzymatic method with an automatic 
analyzer (Hitachi 7600-210; Hitachi Medical Corp., Tokyo, Japan) at Kotobiken Medical 
Laboratories, Inc. The standardization of lipid measurement was performed with the aid of the 
Osaka Medical Center for Health Science and Promotion, an international member of the US 
National Cholesterol Reference Method Laboratory Network (CRMLN) (19).   
 
Statistical Analysis  
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The paired Student’s t-test was used to compare the mean values of baseline cardiovascular risk 
characteristics and blood sFas levels in cases and control subjects. The χ2 test was used to 
compare percentages of cases and control subjects. Also in control subjects, differences in 
baseline risk characteristics were tested according to the sex-specific quartiles of blood sFas 
levels by the analysis of covariance. The odds ratios (ORs) and corresponding 95% confidence 
intervals (CIs) for mortality from total stroke, stroke subtype and coronary heart disease 
according to the sex-specific quartiles and 1-SD increment of sFas were calculated by means of 
conditional logistic regression models. Cut points of the quartile analyses were determined on the 
distribution of control subjects. Linear regression was employed to test for linear trends across 
sFas categories by using a median variable of sFas for each biomarker category. Covariates for 
the adjustment included serum total cholesterol levels (mmol/L: continuous), cigarette smoking 
status (non and current), current ethanol intake (non and current), and self-reported histories of 
physician’s diagnosis hypertension and diabetes mellitus (yes vs. no) as well as matching for sex, 
age, area of residence and year of serum storage.  
All p-values for statistical tests were two-tailed and values <0.05 were considered to represent 
represented statistical significance. The SAS statistical package version 9.4 (Statistical Analysis 
System Inc., Cary, NC) was used for analyses. 
 
Results 
During the median 9-year follow-up, we identified 97 (53 and 44) deaths from coronary heart 
diseases and 233 deaths from total stroke (121 in men and 112 in women) including 49 (18 and 
31) subarachnoid hemorrhages, 55 (27 and 28) intraparenchymal hemorrhages, and 71 (44 and 
27) ischemic strokes. 
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Table 1 shows mean values and prevalence of cardiovascular risk characteristics and 
biomarkers for cases compared with control subjects. The average age was 68 years for total 
stroke, 62 years for subarachnoid hemorrhage, 67 years for intraparenchymal hemorrhage, 70 
years for ischemic stroke, and 67 for coronary heart disease. The prevalence of hypertension and 
current smokers was higher in cases with total stroke than controls; the case-control difference in 
hypertension was evident for hemorrhagic strokes, and that in smoking was so for ischemic 
stroke. The prevalence of diabetes mellitus tended to be higher in cases with coronary heart 
disease than controls. Mean serum total cholesterol levels were lower in cases with total stroke, 
especially intraparenchymal hemorrhage than in controls. Mean sFas levels were higher in cases 
with total stroke, especially subarachnoid hemorrhage than controls. Risk characteristics 
according to sex-specific quartiles of blood sFas levels in the control subjects are shown in 
Supplemental Table 1. 
Table 2 presents age-, sex- and community-matched, as well as multivariable odds ratios (95% 
CIs) for mortality from total stroke, stroke types and coronary heart disease by quartiles of and 1-
SD increment in sFas levels. Blood sFas levels were inversely associated with mortality from 
subarachnoid hemorrhage in both quartile and continuous analyses. Even after further adjustment 
for cardiovascular risk factors, the association with sFas remained statistically significant. The 
multivariable odds ratio (95%CI) for subarachnoid hemorrhage for the highest vs. lowest 
quartiles of sFas was 3.07 (0.52-18.0; P for trend = 0.07), and that for 1-SD increment (1.3 ng/ml 
in both men and women) of sFas was 4.04 (1.07-15.3; P = 0.04). 
The association between sFas levels and mortality from subarachnoid hemorrhage was 
similarly observed for men and women with no sex interaction; P for interaction = 0.52 (not 
shown in table). There were no associations of sFas levels with mortality from intraparenchymal 
hemorrhage, ischemic stroke or coronary heart disease. 
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Discussion 
Our nested case-control study performed as part of a large prospective study showed a positive 
association between Blood levels of sFas and risk of mortality from subarachnoid hemorrhage. 
These associations persisted even after major cardiovascular risk factors were taken into account, 
and similarly observed for both men and women.  
The scope of previous studies that examined the association between sFas and CVD was 
limited to describe an activation of the Fas system after the onset of cardiovascular events that 
fades gradually after the case is stabilized (8-12). None of those studies has examined the 
prospective associations between sFas and cardiovascular endpoints. To our knowledge, the 
current nested case-control study is the first to show a prospective positive association between 
blood sFas and risk of subarachnoid haemorrhage.  
Mechanisms for the increased risk of mortality from subarachnoid hemorrhage associated with 
higher blood sFas levels are suggested as follows. The expressions of Fas-associated death 
domain protein, the cytoplasmic domain of Fas, as well as tumor necrosis factor α were increased 
in cerebral aneurysm samples of patients with subarachnoid hemorrhage compared with samples 
of superficial temporal arteries of control subjects (20,21). Since apoptosis is a key pathology for 
cerebral aneurysm in rats (22) and humans (23), in particular ruptured aneurysms (24), our 
finding on the associations of blood sFas levels with risk of subarachnoid hemorrhage is plausible. 
Blood sFas could be a promising biomarker for detecting subjects at high risk of subarachnoid 
hemorrhage. 
Blood sFas levels, however, were not associated with risk of other types of stroke, or risk of 
coronary heart disease, while they were shown to be increased in subjects with or at high risk of 
ischemic heart disease (8-10). Moreover, one study showed that sFas levels were associated with 
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risk of ischemic stroke; HR (95% CI) for 1- SD increment was 1.31 (1.13-1.51; P=0.004) (25). 
Further research is needed to configure the mechanisms by which blood sFas associates with 
ischemic and hemorrhagic cardiovascular events. 
The strengths of the present study are its prospective design for large community-based 
samples, the comprehensive nature of the cardiovascular surveys for exposure and confounding 
variables, the systematic surveillance for mortality outcomes and measuring the biomarkers of 
interest in a single laboratory with satisfactory reliability and precision.  
However, our study has several limitations. First, approximately only 35% of the total 
participants in health examinations with high participant rates had provided blood samples. 
However, no apparent differences were found in age-adjusted mean values or proportions of 
major cardiovascular risk factors between the subjects who had and who had not provided blood 
samples (16). Thus, the selection bias may be small for the evaluation of the biomarkers-
cardiovascular mortality association. Second, we used frozen serum to estimate biomarkers 
concentrations and did not examine long-term changes in the stored serum samples. We also 
confirmed that those serum biomarkers remained stable in serum samples stored up to 9 years at -
70OC (17). Third, the association of borderline statistical significance with sFas levels in the 
multivariable categorical analysis could be attributable to the low statistical power. The analysis 
for 1-SD increment of log-transformed blood levels of sFas showed significant inverse 
associations. Last, we used the mortality data, not incidence data as endpoints, which biased to 
severe types of stroke and also liable to misclassification. As for stroke, however, the widespread 
use of computed tomography scans, even in Japanese local hospitals, since the 1980s has 
probably made the death certificate diagnosis of total stroke and stroke types sufficiently accurate 
(26). Death certificate diagnosis of coronary heart disease may be more problematic since one-
fourth to one-third of the coronary heart disease deaths appearing on the death certificates were 
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contaminated (27,28). The lack of association between biochemical markers and mortality from 
coronary heart disease might be in part due to the contamination of diagnosis and also the small 
number of cases.  
In summary, Blood sFas levels were associated with higher mortality from subarachnoid 
hemorrhage among middle-aged men and women. Our findings support the notion that apoptosis 
may contribute in the development or prognosis of subarachnoid hemorrhage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
Conflict of Interest: None declared for all authors. 
Financial support: 
This study was supported by Grants-in-Aid for Scientific Research from the Ministry of 
Education, Science, Sports and Culture of Japan; Grants-in-Aid for Scientific Research on 
Priority Areas of Cancer and Grants-in-Aid for Scientific Research on Priority Areas of Cancer 
Epidemiology from the Japanese Ministry of Education, Culture, Sports, Science and Technology 
(61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 
11181101, 17015022, 18014011, 20014026, and 20390156); and Comprehensive Research on 
Cardiovascular and LifeStyle Related Diseases (H26-Junkankitou [Seisaku]-Ippan-001).  
Author’s contribution 
Hiroyasu Iso and Akiko Tamakoshi participated in the study concept and design and acquisition 
of data. Hiroyasu Iso, Maruyama Koutatsu and Ehab S. Eshak participated in the study analysis 
and interpretation of data and drafting of the manuscript, and provided statistical expertise. 
Satoyo Ikehara and Kazumasa Yamagioshi participated in interpretation of data, and critical 
revision of the manuscript. 
Acknowledgments 
The authors thank Dr. Yoshinori Ito, of Nagoya University Graduate School of Medicine, Dr. 
Yoshiyuki Watanabe, of Kyoto Prefectural University of Medicine Graduate School of Medical 
Science, Dr. Yutaka Inaba, of Jissen Women’s University, Dr. Kazuo Tajima, of Aichi Cancer 
Center Research Institute, Dr. Kei Nakachi, of Radiation Effects Research Foundation, and all 
staff members involved in this study for their valuable help in conducting the baseline survey and 
follow-up.  
Study Investigators 
13 
 
Members of the JACC Study Group: Dr. Akiko Tamakoshi (present chairperson of the study 
group), Hokkaido University Graduate School of Medicine, Dr. Mitsuru Mori, Sapporo Medical 
University School of Medicine, Dr. Yoshihiro Kaneko, Akita University Graduate School of 
Medicine, Dr. Ichiro Tsuji, Tohoku University Graduate School of Medicine, Dr. Yosikazu 
Nakamura, Jichi Medical School, Dr. Hiroyasu Iso, Osaka University School of Medicine, Dr, 
Kazumasa Yamagishi, Faculty of Medicine, University of Tsukuba, Dr. Haruo Mikami, Chiba 
Cancer Center, Dr. Michiko Kurosawa, Juntendo University School of Medicine Dr. Yoshiharu 
Hoshiyama, Yokohama Soei University, Dr. Naohito Tanabe, University of Niigata Prefecture, 
Dr. Koji Tamakoshi, Nagoya University Graduate School of Health Science, Dr. Kenji Wakai, 
Nagoya University Graduate School of Medicine, Dr. Shinkan Tokudome, National Institute of 
Health and Nutrition, Dr. Koji Suzuki, Fujita Health University School of Health Sciences, Drs. 
Shuji Hashimoto and Hiroshi Yatsuya, Fujita Health University School of Medicine, Dr. Shogo 
Kikuchi, Aichi Medical University School of Medicine, Dr. Yasuhiko Wada, Faculty of Nutrition, 
University of Kochi, Dr. Takashi Kawamura, Kyoto University Health Service, Dr. Yoshiyuki 
Watanabe, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Dr. 
Kotaro Ozasa, Radiation Effects Research Foundation, Dr. Kazuya Mikami, Kyoto Prefectural 
University of Medicine Graduate School of Medical Science, Dr. Chigusa Date, School of 
Human Science and Environment, University of Hyogo, Dr. Kiyomi Sakata, Iwate Medical 
University, Dr. Yoichi Kurozawa, Tottori University Faculty of Medicine, Drs. Takesumi 
Yoshimura and Yoshihisa Fujino, University of Occupational and Environmental Health, Dr. 
Akira Shibata, Kurume University, Dr. Naoyuki Okamoto, Kanagawa Cancer Center, and Dr. 
Hideo Shio, Long-Term Care Health Facility Caretown Minamikusatsu, Shiga. 
 
14 
 
REFRENCES 
1- van der Meer IM, Oei H-HS, Hofman A, Pold HAP, de Jog FH, et al. Soluble Fas, a mediator 
of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. The Rotterdam 
Coronary Calcification Study. Atherosclerosis 2006;189:464-469. 
 
2-Martín-Ventura JL, Blanco-Colio LM, Tuñón J, Muñoz-García B, Madrigal-Matute J, et al. 
Biomarkers in cardiovascular medicine. Rev Esp Cardiol. 2009;62:677-688. 
 
3- Iso H, Cui R, Date C, Kikuchi S, Tamakoshi A. C-reactive protein levels and risk of mortality 
from cardiovascular disease in Japanese: the JACC Study. Atherosclerosis. 2009;207:291-297. 
 
4- Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456. 
 
5- Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. Apoptosis. 2009;14:536-
548. 
 
6- Sabri M, Kawashima A, Ai J, Macdonald RL. Neuronal and astrocytic apoptosis after 
subarachnoid hemorrhage: a possible cause for poor prognosis. Brain Res. 2008;1238:163-1671. 
 
7- Hasegawa Y, Suzuki H, Sozen T, Altay O, Zhang JH. Apoptotic mechanisms for neuronal 
cells in early brain injury after subarachnoid hemorrhage. Acta Neurochir Suppl. 2011;110(Pt 
1):43-48. 
 
8-Shimizu M, Fukuo K, Nagata S, Suhara T, Okuro M, et al. Increased plasma levels of the 
soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina 
pectoris. J Am Coll Cardiol. 2002;39:585-590. 
 
9- Hébert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, et al. Soluble Fas is a marker of 
coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis. 2001;38:1271-
1276. 
 
10- Sahinarslan A, Boyaci B, Kocaman SA, Topal S, Ercin U, et al. The relationship of serum 
soluble Fas ligand (sFasl) level with the extent of coronary artery disease. Int J Angiol. 
2012;21:29-34. 
 
11- Nishigaki K, Minatoguchi S, Seishima M, Asano K, Noda T, et al. Plasma Fas ligand, an 
inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic 
congestive heart failure. J Am Coll Cardiol. 1997;29:1214-1220. 
 
12- Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, et al. Prognostic value of 
apoptosis markers in advanced heart failure. Eur Heart J. 2009;30:789-796. 
 
13- Delgado P, Cuadrado E, Rosell A, Alvarez-Sabín J, Ortega-Aznar A, et al. Fas system 
activation in perihematomal areas after spontaneous intracerebral hemorrhage. Stroke. 
2008;39:1730-1734. 
 
15 
 
14- Mahovic D, Zurak N, Lakusic N, Sporis D, Zarkovic N, et al. The dynamics of soluble 
Fas/APO 1 apoptotic biochemical marker in acute ischemic stroke patients. Adv Med Sci. 
2013;58:298-303. 
 
15- Ohno Y, Tamakoshi A and the JACC Study Group. Japan collaborative cohort study for 
evaluation of cancer risk sponsored by Monbusho (JACC study). J Epidemiol 2001; 11:144-150. 
 
16- Iso H, Cui R, Date C, Kikuchi S, Tamakoshi A. C-reactive protein levels and risk of mortality 
from cardiovascular disease in Japanese: the JACC Study. Atherosclerosis. 2009 ;207:291-297. 
 
17- Ito Y, Nakachi K, Imai K, Hashimoto S, Watanabe Y, et al. Satability of frozen serum levels 
of insulin-like growth factor-1, insulin-like growth factor-II, insulin-like growth factor binding 
protein-3, transforming growth factor beta, soluble Fas, and superoxide dismutase activity for the 
JACC study. J Epidemiol 2005;15(Suppl 1):S67-73. 
 
18- Tamakoshi A, Nakachi K, Ito Y, Lin Y, Yagyu K, et al. Soluble Fas level and cancer 
mortality: findings from a nested case-control study within a large-scale prospective study. Int J 
Cancer. 2008 15;123:1913-1916. 
 
19- Nakamura M, Sato S, Shimamoto T. Improvement in Japanese clinical laboratory 
measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method 
Laboratory Network. J Atheroscler Thromb. 2003;10:145-153. 
 
20- Jayaraman T, Berenstein V, Li X, Mayer J, Silane M, et al. Tumor necrosis factor alpha is a 
key modulator of inflammation in cerebral aneurysms. Neurosurgery. 2005;57:558-64. 
 
21-Starke RM, Raper DM, Ding D, Chalouhi N, Owens GK, et al. Tumor necrosis factor-α 
modulates cerebral aneurysm formation and rupture. Transl Stroke Res. 2014;5:269-277. 
 
22- Kondo S, Hashimoto N, Kikuchi H, Hazama F, Nagata I, et al. Apoptosis of medial smooth 
muscle cells in the development of saccular cerebral aneurysms in rats. Stroke 1998;29:181-189. 
 
23- Hara A, Yoshimi N, Mori H. Evidence for apoptosis in human intracranial aneurysms. Neurol 
Res 1998;20:127-130. 
 
24- Pentimalli L, Modesti A, Vignati A, Marchese E, Albanese A, et al. Role of apoptosis in intra 
cranial aneurysm rupture. J Neurosurg. 2004;101:1018-1025. 
 
25-Lind L, Siegbahn A, Lindahl B, Stenemo M, Sundström J, et al. Discovery of new risk 
markers for ischemic stroke using a novel targeted proteomics chip. Stroke. 2015;46:3340-3347. 
 
26- Sasamamoto T, Iida M, Tanigaki M, Naito Y, et al. A population-based study of the 
proportion by type of stroke determined by computed tomography scan. Nippon Koshu Eisei 
Zasshi 1991;38:901-909. 
 
16 
 
27- Yamashita T, Ozawa H, Aono H, Hosokawa H, Saito I, et al. Heart disease deaths on death 
certificates re-evaluated by clinical records in a Japanese city. CHD diagnosis. Jpn Circ J 
1997;61:331-338. 
 
28-Baba S, Ozawa H, Sakai Y, Terao A, Konishi M, et al. Heart disease deaths in a Japanese 
urban area evaluated by clinical and police records. Circulation 1994; 89:109-115.
17 
 
Table 1. Mean values ± standard deviations and proportions of cardiovascular risk characteristics and blood sFas levels in cases and controls. 
 Total stroke Subarachnoid hemorrhage Intraparenchymal hemorrhage Ischemic stroke Coronary heart disease 
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
No. of subjects 233 233 49 49 55 55 71 71 97 97 
Men, % 51.9 51.9 36.7 36.7 50.9 50.9 62.0 62.0 54.6 54.6 
Age, year 67.7±8.1 67.0 ±7.5 61.9±9.7 61.8±9.4 66.6±7.8 66.3±7.5 70.3±6.4 69.1±5.5 67.3±7.6 66.9±7.3 
Total cholesterol, mmol/L 4.98±1.01b 5.26±1.03 5.01±0.94 5.32±1.25 4.83±1.12 a 5.31±1.00 5.01±0.91 5.19±0.90 5.42±0.99 5.26±1.17 
Current smoker, % 38.4a 27.0 31.9 23.9 34.0 27.1 47.6 a 27.3 41.4 33.7 
Ethanol intake, g/day 35±25 31±23 33±21 28±25 41±34 28±22 29±19 31±19 31±23 26±24 
History of hypertension, % 44.9 b 31.5 44.4 a 23.4 44.0 a 24.5 45.3 32.8 41.4 33.7 
History of diabetes mellitus, % 5.3 5.7 9.3 4.4 0.0 2.1 3.3 9.5 12.8 4.6 
sFas, ng/ml 2.4±1.4 2.2±1.3 2.3±1.4 a 2.0±1.3 2.6±1.4 a 2.4±1.3 2.4±1.4 2.3±1.4 2.2±1.4 2.2±1.3 
Difference from controls: a p<0.05, b p<0.01. 
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Table 2. Conditional odds ratios (ORs) and 95% confidence intervals (CIs) for mortality from 
total stroke, stroke types and coronary heart disease according to quartiles of sFas levels. 5 
 
 Quartiles of blood soluble Fas levels a OR per 1 SD b 
increment 
P value 
 Q1(Low) Q2 Q3 Q4 (High) P-trend 
Total stroke        
No. of cases 51 54 52 76    
No. of controls 54 66 57 56    
Age, sex and community-matched OR 1.00 0.91 (0.53-1.57) 1.01 (0.56-1.81) 1.55 (0.87-2.75) 0.07 1.51 (1.06-2.16) 0.02 
Multivariable OR c 1.00 0.96 (0.53-1.74) 1.13 (0.59-2.16) 1.38 (0.74-2.58) 0.22 1.37 (0.92-2.03) 0.12 
Subarachnoid hemorrhage        
No. of cases 13 11 10 15    
No. of controls 18 16 6 9    
Age, sex and community-matched OR 1.00 1.10 (0.35-3.48) 2.90 (0.70-12.0) 3.40 (0.82-14.1) 0.05 3.40 (1.12-10.3) 0.03 
Multivariable OR c 1.00 1.21 (0.21-6.86) 4.44 (0.72-27.4) 3.07 (0.52-18.0) 0.07 4.04 (1.07-15.3) 0.04 
Intraparenchymal hemorrhage        
No. of cases 6 14 13 22    
No. of controls 6 15 20 14    
Age, sex and community-matched OR 1.00 1.23 (0.26-5.76) 0.74 (0.16-3.29) 1.84 (0.38-8.96) 0.27 1.53 (0.82-2.85) 0.18 
Multivariable OR c 1.00 1.72 (0.20-14.7) 0.65 (0.67-6.43) 1.23 (0.13-11.5) 0.95 0.86 (0.34-2.17) 0.75 
Ischemic stroke        
No. of cases 20 13 13 25    
No. of controls 14 22 15 20    
Age, sex and community-matched OR 1.00 0.37 (0.13-1.06) 0.54 (0.19-1.55) 0.93 (0.36-2.42) 0.81 1.29 (0.72-2.30) 0.39 
Multivariable OR c 1.00 0.49 (0.14-1.65) 0.68 (0.2-2.31) 1.26 (0.41-3.89) 0.45 1.69 (0.85-3.36) 0.13 
Coronary heart disease        
No. of cases 30 18 22 27    
No. of controls 24 28 22 23    
Age, sex and community-matched OR 1.00 0.55 (0.25-1.21) 0.78 (0.35-1.73) 1.02 (0.40-2.63) 0.84 1.00 (0.56-1.78) 1.00 
Multivariable OR c 1.00 0.46 (0.19-1.10) 0.73 (0.28-1.89) 0.78 (0.25-2.42) 0.86 0.81 (0.40-1.66) 0.56 
a Ranges of sFas in quartiles were ≤1.9, 1.9-2.3, 2.3-2.9, 2.9+ ng/ml in men and ≤1.9, 1.9-2.3, 2.3-2.7, 2.7+ ng/ml in women. 
b 1-SD of of sFas were 1.3 ng/ml in men and 1.3 ng/ml in women. 
c Multivariable OR: further adjusted for current smoking status (yes/no), alcohol consumption (current/non-drinker), serum total 
cholesterol levels (continuous) and history of diabetes mellitus and hypertension (yes/no).10 
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Supplemental Table 1. Age- and sex-adjusted mean values (standard errors) and proportions of cardiovascular risk characteristics in control 
subjects according to quartiles of blood soluble Fas levels. 
 Quartiles of blood soluble Fas levels a 
 Q1(Low) Q2 Q3 Q4 (High) P-trend 
No. of subjects 78 94 79 79  
Men, % 51.3 52.1 54.4 53.2 0.98 
Age, year 66.1 65.6 67.1 69.4 <0.01 
Total cholesterol, mmol/L 5.2 (0.12) 5.3 (0.11) 5.3 (0.12) 5.2 (0.12) 0.82 
Current smoker, % 23.6 29.6 22.2 33.9 0.23 
Ethanol intake, g/day 22.0 (3.93) 22.5 (4.05) 20.9 (4.74) 18.3 (6.45) 0.60 
Body mass index, kg/m2 22.3 (0.36) 22.7 (0.33) 23.0 (0.37) 22.9 (0.37) 0.20 
History of hypertension, % 24.3 31.6 35.3 38.8 0.06 
History of diabetes mellitus, % 8.1 4.9 2.9 5.4 0.44 
sFas, ng/ml* 1.5 2.0 2.5 3.2 <0.01 
*Ranges of blood sFas in quartiles were ≤1.9, 1.9-2.3, 2.3-2.9, 2.9+ ng/ml in men and ≤1.9, 1.9-2.3, 2.3-2.7, 2.7+ ng/ml in women. 
